A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

• Main Authors: Ozhan Ocal (Author), Victor Pashkov (Author), Rahul K. Kollipara (Author), Yalda Zolghadri (Author), Victoria H. Cruz (Author), Michael A. Hale (Author), Blake R. Heath (Author), Alex B. Artyukhin (Author), Alana L. Christie (Author), Pantelis Tsoulfas (Author), James B. Lorens (Author), Galvin H. Swift (Author), Rolf A. Brekken (Author), Thomas M. Wilkie (Author)
• Format: Book
• Published: The Company of Biologists, 2015-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the developmen...